Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ionis Pharmaceuticals Inc. Common Stock (IONS) vs Strategy Inc. (MSTR) Price & Performance

Ionis Pharmaceuticals Inc. Common StockTrade
Strategy Inc.Trade

Price performance (Past 24H)

Key statistics

Ionis Pharmaceuticals Inc. Common Stock vs Strategy Inc. — how do they compare? Ionis Pharmaceuticals Inc. Common Stock trades at $43.2 (market cap $7.04B), while Strategy Inc. trades at $141.13 (market cap $64.44B). The key difference: Strategy Inc. is far larger — about 9.2× Ionis Pharmaceuticals Inc. Common Stock's market cap, and Strategy Inc. is trading nearer its 52-week high, Ionis Pharmaceuticals Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ionis Pharmaceuticals Inc. Common Stock for 0 Days and Strategy Inc. for 113 Days on average.

IONSMSTR
Market Cap
$7.04B$64.44B
Volume
2,977,44012,273,653
Sector
HealthTechnology
52-Week High
$86.50$301.91
52-Week Low
$42.38$82.31
Typical Hold Time
0 Days113 Days
Enterprise Value
$6.60B$83.20B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ionis Pharmaceuticals Inc. Common Stock

No Aura AI signal available yet.

Strategy Inc.

MSTR stock trades at $143.24, down 6.18% today, with technical indicators showing neutral momentum near key support at $142. The company reported Q2 2026 EPS of -$24.45, missing expectations of -$2.19, continuing a trend of significant earnings misses. Despite negative profitability metrics including a -6,102.96% net income margin, analyst consensus remains bullish with 62% buy ratings and a $253.36 price target representing 77% upside potential from current levels.

The investment case hinges on analyst optimism despite fundamental challenges, with Citigroup recently doubling its price target to $240. Key risks include persistent negative earnings, high valuation multiples (P/S of 96.6), and substantial debt load of $7.19 billion. Cash flow trends show heavy reliance on financing activities to support operations and investments.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IONS
100% Buy0% Sell
Avg holding period · 0 Days
MSTR
90% Buy10% Sell
Avg holding period · 113 Days

Top news

Latest headlines on both assets

About Ionis Pharmaceuticals Inc. Common Stock

Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.

Read more on IONS →

About Strategy Inc.

MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web

Read more on MSTR →